152 related articles for article (PubMed ID: 33797309)
21. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
22. TATTOO-ASSOCIATED CASES OF POSTERIOR SEGMENT UVEITIS WITH VOGT-KOYANAGI-HARADA DISEASE-LIKE FEATURES.
Kesav NP; Kaplan AJ; Hwang CK; Okeagu C; Sen HN
Retin Cases Brief Rep; 2022 Jul; 16(4):457-460. PubMed ID: 32502130
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
24. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
Czichos C; Wawrzynów B; Chamalis C; von Jagow B
Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
[No Abstract] [Full Text] [Related]
25. [Rare form of uveitis with neurological symptoms: the Vogt-Koyanagi-Harada uveomeningoencephalitic syndrome].
Kätterer C; Kaeser HE; Steiger U
Schweiz Med Wochenschr; 1992 Feb; 122(8):269-74. PubMed ID: 1542780
[TBL] [Abstract][Full Text] [Related]
26. Vogt Koyanagi Harada syndrome in a 15-year-old girl, steroids side effects and recurrences.
Yıldırım G; Çavdarlı C; Özdemir EY; Alp MN
Turk J Pediatr; 2021; 63(3):527-532. PubMed ID: 34254501
[TBL] [Abstract][Full Text] [Related]
27. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
28. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
29. Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.
Martin TD; Rathinam SR; Cunningham ET
Retina; 2010; 30(7):1113-21. PubMed ID: 20168275
[TBL] [Abstract][Full Text] [Related]
30. Vogt-Koyanagi-Harada syndrome in a 4-year old child.
Cunningham ET; Demetrius R; Frieden IJ; Emery HM; Irvine AR; Good WV
Am J Ophthalmol; 1995 Nov; 120(5):675-7. PubMed ID: 7485374
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
Abu El-Asrar AM; Dheyab A; Khatib D; Struyf S; Van Damme J; Opdenakker G
Ocul Immunol Inflamm; 2022 Apr; 30(3):750-757. PubMed ID: 32990482
[TBL] [Abstract][Full Text] [Related]
32. [Vogt-Koyanagi-Harada syndrome in children].
Laghmari M; Karim A; Ibrahimy W; Essakalli NH; Mohcine Z
J Fr Ophtalmol; 2002 Jun; 25(6):636-40. PubMed ID: 12223954
[TBL] [Abstract][Full Text] [Related]
33. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Fujita K; Yamamoto Y; Kanai O; Okamura M; Hashimoto M; Nakatani K; Sawai S; Mio T
Thorac Cancer; 2020 Jan; 11(1):15-18. PubMed ID: 31701630
[TBL] [Abstract][Full Text] [Related]
34. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
; ; . PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
